News & Reports

Sysmex Q1 FY2027: Sales surge 24% but China slowdown persists

Sysmex reported a 23.6% jump in first-quarter revenue to 130,674 million yen for FY2027, with operating profit up 39.5% to 14,821 million yen. Net income attributable to owners of the parent surged 90.9% to 8,691 million yen, but China was a clear weak spot.

FY2027 Q1 (Apr-Jun 2026)

Asahi Intecc FY2026 Full Year: Operating Profit Jumps 50% to Record High

Asahi Intecc reported full-year results for FY2026 with revenue of 145,419 million yen, up 21.2% year on year, while operating profit rose 50.3% to 45,218 million yen and net income attributable to owners of the parent surged 151.8% to 32,075 million yen. Strong catheter demand, a weaker yen, and productivity gains drove the record results across all profit levels.

FY2026 Full Year

Olympus Q1 FY2027: Operating profit surges 74% on endoscope demand

Olympus reported a sharp rise in first-quarter earnings for FY2027, with revenue up 16.4% to ¥240.4 billion and operating profit surging 74.4% to ¥28,951 million, driven by strong gastrointestinal endoscope sales in North America and Europe. Net income attributable to owners of the parent more than doubled, climbing 112.5% to ¥19,102 million.

FY2027 Q1 (April–June 2026)

Nihon Kohden Q1 FY2027: Overseas growth can't offset Japan decline, swings to loss

Nihon Kohden posted a ¥983 million operating loss in Q1 FY2027, as a 15% domestic sales drop outweighed 10.3% overseas growth. Revenue slipped 5.2% to ¥47.4 billion. Full-year forecasts were held steady, betting on a H2 recovery.

Q1 FY2027 (Apr-Jun 2026)

Olympus: FDA alert restricts U.S. imports, forecast unchanged

Olympus said the FDA issued an import alert for some products made at three group facilities in Japan, restricting U.S. imports until further notice. It sees no additional impact on fiscal 2027 results and kept its forecast unchanged.

Olympus: FDA Warning Letter Issued for Six Facilities; No Earnings Impact

Olympus received a Warning Letter from the US FDA regarding quality management at six facilities. The company stated the disclosure has no impact on consolidated financial results, reassuring investors of operational stability.

Terumo: Book $97.5B Loss on CSL Deal Cut, Slashes Profit Outlook by Nearly 40 Percent

Medical equipment giant Terumo will recognize a massive loss of approximately $610 million due to the termination of a key supply contract. Consequently, the company has revised its full-year operating profit forecast downward by roughly 38 percent.

Sysmex: To reduce outstanding shares by 3.4 pct to boost capital efficiency

Sysmex announced the cancellation of 21.14 million treasury shares as of Sept. 30, reducing total issued shares by roughly 3.4 pct. This move aims to strengthen capital efficiency and is expected to lift earnings per share.

Nihon Kohden: Japan Activation Capital Expands Stake to 6.48 Percent

Japan Activation Capital's funds have acquired 10.41 million shares of Nihon Kohden, expanding its voting rights stake to 6.48 percent. This transaction marks a significant shift in the company's major shareholder structure.